秦环龙、秦楠等:新冠肺炎患者接受益生菌辅助治疗后的肠道菌群恢复情况
创作:aluba 审核:aluba 01月04日
  • 招募13名新冠肺炎患者、15名健康对照及15名其它肺炎对照,鉴定出了新冠肺炎相关的肠道菌群及上呼吸道菌群变化;
  • 8名新冠肺炎患者接受益生菌辅助治疗,在治疗前、治疗7天后及治疗14天后分析粪便菌群;
  • 6名患者在治疗结束后的粪便菌群组成得到恢复,与健康对照更为相似,表现为新冠肺炎相关菌群转录组增加(大肠杆菌、肺炎克雷伯菌等)的减少,以及新冠肺炎相关菌群转录组降低(柔嫩梭菌群等)的增加。
主编推荐语
aluba
同济大学附属第十人民医院的秦环龙团队、秦楠团队及深圳市第三人民医院的卢洪洲团队在Clinical and Translational Medicine上发表的一项最新研究,对比鉴定了新冠肺炎患者的肠道菌群及上呼吸道菌群的特异性变化,并分析了患者在接受益生菌辅助治疗后的肠道菌群恢复情况。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!

The volatile and heterogeneous gut microbiota shifts of COVID-19 patients over the course of a probiotics-assisted therapy

新冠肺炎患者接受益生菌辅助治疗后的肠道菌群变化

10.1002/ctm2.643

2021-12-28, Other

Abstract & Authors:展开

Abstract:收起
It has been reported that up to half but as low as 3% of COVID-19 patients had gastrointestinal symptoms (e.g., diarrhoea, nausea, and vomiting)1-3 and substantial gut microbiota shifts,4, 5 a testament to the importance of the microbial community in the therapeutic responses and prognosis of the disease. Nevertheless, given the seriously rapid progression of COVID-19,6 it is important to investigate the microbial dynamics during the illness and convalescence stages. Here, we employed a probiotics-assisted therapy to treat a group of COVID-19 patients, and their dynamics of gut microbiota and clinical manifestations were monitored throughout the treatment.

First Authors:
Chunyan Wu,Qian Xu,Zhan Cao

Correspondence Authors:
Nan Qin,Hongzhou Lu,Huanlong Qin

All Authors:
Chunyan Wu,Qian Xu,Zhan Cao,Dengdeng Pan,Ying Zhu,Sheng Wang,Danping Liu,Zhigang Song,Wei Jiang,Yumeng Ruan,Yongkun Huang,Nan Qin,Hongzhou Lu,Huanlong Qin

评论